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Abstract
We investigated the genetic, phenotypic and interferon status of 46 patients from 37 families with neurological disease due to mutations in ADAR1. The clinico-radiological phenotype encompassed a spectrum of Aicardi-Goutières syndrome (AGS), isolated bilateral striatal necrosis (BSN), spastic paraparesis with normal neuroimaging, a progressive spastic dystonic motor disorder, and adult-onset psychological difficulties with intracranial calcification. Homozygous missense mutations were recorded in five families. We observed a p.Pro193Ala variant in the heterozygous state in 22 of 23 families with compound heterozygous mutations. We also ascertained 11 cases from nine families with a p.Gly1007Arg dominant-negative mutation, which occurred de novo in four patients, and was inherited in three families in association with marked phenotypic variability. In 50 of 52 samples from 34 patients we identified a marked upregulation of type I interferon stimulated gene transcripts in peripheral blood, with a median interferon score of 16.99 (interquartile range (IQR): 10.64 -25.71) compared to Introduction Adenosine deaminases acting on RNA (ADARs) catalyse the hydrolytic deamination of adenosine to inosine in double-stranded RNA, and thereby potentially alter the information content and structure of cellular RNAs 1 . ADAR1 is encoded by a single- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 7 copy gene that maps to human chromosome 1q21 and is present in two main isoforms in mammalian cells. In mice, a loss of ADAR1 activity leads to a dramatic upregulation of interferon-stimulated gene (ISG) expression, which is dependent on the editing activity of ADAR1 and specific to the interferon-inducible full-length p150 isoform of the protein [2] [3] [4] .
In 2012 we reported mutations in ADAR1 to cause a phenotype consistent with the infantile encephalopathy Aicardi-Goutières syndrome, and demonstrated that, similar to the Adar1-null mouse, the mutant genotype was associated with an upregulation of type I interferon signalling 5 . Further to this, in 2014, we described both bilateral striatal necrosis, sometimes occurring after a trivial childhood infection, and otherwise nonsyndromic, slowly progressive spastic paraparesis associated with normal intellect to occur due ADAR1 dysfunction, again in association with the enhanced expression of type I interferon induced gene transcripts [6] [7] [8] . These data indicate that neurological disease can occur through inappropriate induction of the innate immune system by selfderived nucleic acids.
Here we present an update of our experience of screening for ADAR1 mutations, describing the clinical, radiological, molecular and interferon biomarker characteristics of a cohort of 46 patients from 37 families with neurological dysfunction due to mutations in ADAR1. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 8 We ascertained clinical and molecular data through direct contact and / or via collaborating physicians. The study was approved by the Leeds (East) Research Ethics Committee (reference number 10/H1307/132), and the Comité de Protection des Personnes (ID-RCB / EUDRACT: 2014-A01017-40). 
Materials and methods

Patients and methods
Mutational analysis
Primers were designed to amplify the coding exons of ADAR1 ( Supplementary Table 1 ).
Purified PCR amplification products were sequenced using BigDye terminator chemistry and an ABI 3130 DNA sequencer. Mutation description is based on the reference cDNA sequence NM_001111.4, with nucleotide numbering beginning from the first A in the initiating ATG codon. Variants were assessed using the in silico programmes SIFT (http://sift.jcvi.org) and Polyphen2 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Molecular data
We collected data on 46 patients from 37 families of pan-ethnic origin with either biallelic mutations in ADAR1 (28 families) or the single known dominant-negative mutation p.Gly1007Arg (nine families)( Table 1 ; Figure 1 ). In four families the p.Gly1007A mutation was considered to have occurred de novo, whilst in three families inheritance was confirmed or inferred (2 paternal half-siblings born to an unaffected father unavailable for testing), with somatic mosaicism recorded in one case. In two families inheritance could not be determined because DNA from both parents was not available. We observed three distinct homozygous mutations in five families (two families each sharing the same mutation), in four of which the parents were knowingly related. All of these mutations were missense. Of 23 families with compound heterozygous mutations, 22 carried the p.Pro193Ala mutation on one allele. In 13 of 22 families segregating this p.Pro193Ala substitution the second molecular lesion was a null or splicing variant.
Clinical radiological phenotype
Clinical radiological characteristics of all patients are summarised in Table 2 , and characteristic radiological appearances summarised in Figure 2 . Median age of disease onset was 14 months (range: birth -30 years). We observed 21 and 25 affected females and males respectively. Although spasticity and dystonia were common features present in the majority of patients, clinically and radiologically distinct phenotypes could be defined, including classical Aicardi-Goutières syndrome (15 patients), bilateral striatal necrosis (16 patients), apparently isolated spastic paraparesis (one patient) / tetraparesis (two patients) and a progressive spastic dystonic motor disorder (seven patients). In two of these latter cases the initial presentation was of isolated lower limb spasticity, with a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Interferon status
We derived 52 interferon scores from 34 patients, 50 of which were abnormal, with a median interferon score across the group of 16.99 (interquartile range (IQR): 10.64 -25.71) compared to controls (median: 0.93, IQR: 0.57 -1.30)( Figure 4 ). Positive scores were observed up to 25 years after disease onset. We also tested 20 interferon scores from 16 parental carriers of a recessive mutation in ADAR1. Two samples from seven parents heterozygous for the recurrent p.Pro193Ala mutation demonstrated a positive interferon score, versus six samples from nine parents carrying a different mutation ( Supplementary Figure 1 ).
Discussion
In 2012, ADAR1 mutations were described in the context of the early-onset encephalopathy Aicardi-Goutières syndrome, associated with the presence of intracranial calcification, white matter disease and severe developmental delay 5 .
Subsequently, in 2014, mutations in ADAR1 were also shown to underlie cases of apparently non-syndromic bilateral striatal necrosis, and of isolated spastic paraparesis with normal neuroimaging 6, 7 . Here we confirm these associations, thus emphasising the need to consider ADAR1-related disease in a number of distinct clinical scenarios should be thought of in the context of a motor disorder characterised by spasticity and dystonia. The onset of disease can occur after a period of normal development, sometimes associated with a rapid loss of skills, or a much slower progression over many years. Assessments using the GMFCS, MACS and CFCS rating scales indicate that disease outcome in the cases that we have ascertained is frequently severe. It is of note that we observed cases with completely preserved intellect + / -normal neuroimaging in the face of significant motor disability.
Our own research focus is biased towards the ascertainment of paediatric disease.
However, Tojo et al. described a female patient with the dominant-negative p.Gly1007Arg mutation, presenting at age 17 years with gait disturbance and dystonic posturing of the legs, who experienced intellectual deterioration from 21 years of age, and became wheelchair bound a year later 13 . Together with our observation of an adult female whose clinical phenotype only became evident at age 30 years, it is clear that later onset disease can occur due to ADAR1 deficiency. This latter case also illustrates the significant intra-familial variability which can be seen in association with ADAR1 dysfunction, the mother presenting in adulthood with subtle psychological disturbance, whilst her son experienced a devastating early-onset encephalopathy. which is recorded on 602 of 282,636 alleles in the gnomAD database, was not observed in the homozygous state in our cohort. That this variant was seen in combination with a null mutation in 13 families suggests that homozygosity for the p.Pro193Ala allele leads to a milder, later-onset or distinct phenotype not ascertained here, or may not be associated with disease. Perhaps of note, the gnomAD database includes one individual homozygous for this mutation. Finally, our molecular data highlight the dominantnegative p.Gly1007Arg mutation, which can occur de novo, or be inherited with variable expression and / or non-penetrance at least into mid-adult life. The proximity of Gly1007 to the backbone of its RNA ligand, and the possibility for an arginine residue to make polyvalent interactions there, suggests a mechanism whereby Arg1007 might bind more tightly to RNA and thus act as a competitive inhibitor of wild-type protein, whilst being itself catalytically inactive 14 . In keeping with this model, we previously demonstrated that a plasmid expressing Gly1007Arg showed stronger inhibition of wild-type ADAR1 than equivalent amounts of a plasmid expressing catalytic inactive ADAR1 5 .
More than 130 different ADAR1 mutations have been documented in patients with DSH, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Loss-of-function mutations in ADAR1 have been classified within the so-called type I interferonopathy grouping, a novel set of inborn errors of immunity where it is proposed that an upregulation of type I interferon signalling is central to disease pathogenesis 17,18 .
The Aicardi-Goutières syndrome phenotype can arise due to mutations in any one of seven genotypes within this grouping (AGS1-7: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1 and IFIH1), and apparently isolated spastic paraparesis has been reported in patients mutated in three of these genes (RNASEH2B, ADAR1 and IFIH1). In contrast, in an overview of 374 patients from 299 families with mutations in AGS1-7, bilateral striatal necrosis, the most frequently ascertained phenotype in the current series, was only recorded in the context of ADAR1-related disease, suggesting discrete factors relevant to gene / protein expression and disease mechanism consequent upon ADAR1 dysfunction 19 . Possibly also reflective of this apparent specificity, in comparison to other genotypes, is the frequency of clinical progression, and the low risk of developing glaucoma and chilblain-like lesions (since we recorded no examples of the former, and only two cases of the latter in our cohort). The consistent finding of a positive interferon signature in peripheral blood in the series of patients reported here indicates the potential utility of this biomarker as a screening test for ADAR1-related disease, for the interpretation of ADAR1 genetic sequence variants of uncertain significance, and in the possible monitoring of treatment efficacy as anti-interferon therapies are developed 20,21 . We emphasise that the interferon signature remains elevated many years after disease onset, providing evidence of ongoing pathology. ADAR1 is expressed throughout the brain including the basal ganglia (http://www.brain-map.org), and it has been shown that a loss of ADAR1 renders cells more susceptible to apoptosis following stress, including infection 22 . We cannot rule out the possibility that the occurrence of fevers prior to frank neurological regression represents a prodrome in some cases. However, a history of vaccination or an apparently discrete infectious episode in several patients considered to be completely developmentally normal prior to disease onset, of whom 12 demonstrated bilateral striatal necrosis on neuroimaging, raises the possibility that the acute degeneration of striatal tissue seen in many patients with ADAR1 mutations might relate to a rapid induction of apoptosis triggered by viral infection / metabolic stress. Beyond this possibility, there is strong evidence that interferon is a neurotoxin 23-27 , and we consider it likely that inappropriate and chronic exposure to type I interferons may be directly relevant to the ADAR1-related neurological phenotypes described here, perhaps induced by dsRNA species which are normally edited by ADAR1, thereby rendering them as immunology inert / marking them as self 1, 3, 4, 28 . These observations highlight the potential utility of treatments for ADAR1-related disease, which recent data suggest might be usefully targeted at antagonism of type I interferon signalling 29 . 
Acknowledgements
We are grateful to the affected families for their involvement in our research, and to all clinicians who contributed samples and clinical data not included here. We thank Marie-Louise Frémond for critical reading of the manuscript. We would like to thank the Exome Aggregation Consortium (ExAC), the Genome Aggregation Database (gnomAD) and the groups that provided exome variant data for comparison. 
Author Contributions
Financial Disclosure/Conflict of Interest
None of the authors have any financial disclosures to report. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  Table 1 . Family structure, ethnicity and molecular data of ascertained ADAR1 mutation-positive cases. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
AGS number
Individuals tested
Consanguinity
